In the latest move to tackle alleged corruption within the pharmaceutical industry, Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly, a major player in the drug manufacturing sector, for purportedly bribing healthcare providers to prescribe its drugs. The suit claims Eli Lilly deliberately violated the Texas Health Care Program Fraud Prevention Act through illicit marketing tactics aimed at peddling their GLP-1 medications, Mounjaro and Zepbound, often used to treat diabetes and aid weight loss, as per a release from the State's Attorney General's Office.
According to the official statement, the pharmaceutical giant is accused of offering "free nurses" and reimbursement support services as illegal inducements to medical providers in Texas to influence prescription rates, the costs of which, in many instances, were covered by Medicaid with the state subsequently incurring millions in tainted claims because of these schemes. “Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Paxton remarked in a stand against the alleged corporate manipulation for profit. "Eli Lilly fraudulently sought to maximize profits at taxpayer expense and put corporate greed over people’s health. I will not stand by while corporations unlawfully manipulate our healthcare system to line their own pockets.”
This legal pursuit is not Paxton's first endeavor in holding drug manufacturers like Eli Lilly accountable, and builds upon his track record of combatting perceived fraudulent activities within the healthcare industry; his office remains adamant in its resolve to confront corporate conduct that is deemed to potentially jeopardize the financial integrity of healthcare programs and, by extension, the well-being of Texas residents. In his official statement, Paxton vowed to continue to stand as a bulwark against corporate interests that may unlawfully exploit the healthcare system and patients it serves.
.jpg){kind=link}